Importantly, the density of TMEM doorways, called TMEM doorway score, in primary breast tumors has been clinically validated as a prognostic marker of distant metastatic recurrence in breast cancer patients with estrogen receptor-positive HER2-negative (ER+/HER2-) disease, independent of other clinical prognostics [12–14]. The gene discussed is ERBB2; the disease is breast cancer.